1100 related articles for article (PubMed ID: 26720597)
1. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
Yüce T; Dökmeci F; Çetinkaya ŞE
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
3. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
5. The effect of EMG biofeedback assisted pelvic floor muscle therapy on symptoms of the overactive bladder syndrome in women: A randomized controlled trial.
Voorham JC; De Wachter S; Van den Bos TWL; Putter H; Lycklama À Nijeholt GA; Voorham-van der Zalm PJ
Neurourol Urodyn; 2017 Sep; 36(7):1796-1803. PubMed ID: 27869312
[TBL] [Abstract][Full Text] [Related]
6. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
7. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
8. Pelvic floor muscle training for overactive bladder symptoms - A prospective study.
Fitz F; Sartori M; Girão MJ; Castro R
Rev Assoc Med Bras (1992); 2017 Dec; 63(12):1032-1038. PubMed ID: 29489983
[TBL] [Abstract][Full Text] [Related]
9. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
10. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
11. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
12. [Yun's optimized pelvic floor training therapy for idiopathic moderate overactive bladder with sexual dysfunction in young and middle-aged women].
Jiao W; Shi CL; He JY; Wu DL; Shi GW; Wang YY
Zhonghua Nan Ke Xue; 2019 Aug; 25(8):707-712. PubMed ID: 32227713
[TBL] [Abstract][Full Text] [Related]
13. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
14. Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.
Jafarabadi M; Jafarabadi L; Shariat M; Rabie Salehi G; Haghollahi F; Rashidi BH
J Obstet Gynaecol Res; 2015 Jan; 41(1):120-6. PubMed ID: 25369726
[TBL] [Abstract][Full Text] [Related]
15. The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial.
Xiao DD; Lv JW; Xie X; Jin XW; Lu MJ; Shao Y
BMC Urol; 2016 Aug; 16(1):49. PubMed ID: 27503124
[TBL] [Abstract][Full Text] [Related]
16. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial.
Kim TH; Jung W; Suh YS; Yook S; Sung HH; Lee KS
BJU Int; 2016 Feb; 117(2):307-15. PubMed ID: 26305143
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
19. Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment.
Bunyavejchevin S
J Obstet Gynaecol Res; 2015 Jun; 41(6):957-61. PubMed ID: 25773663
[TBL] [Abstract][Full Text] [Related]
20. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
Dokmeci F; Cetinkaya SE; Seval MM; Dai O
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]